What is MacroGenics, Inc.'s earnings per share (EPS)?

MacroGenics, Inc. (MGNX) reported diluted earnings per share of -$1.18 for fiscal year 2025. This represents a -10.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MacroGenics, Inc. (MGNX) Financials

MGNX

Trailing 12 months to June 30, 2026

Revenue $183.0M +21.9% YoY

Net Income $60.0M +96.6% YoY

EPS (Diluted) -$0.22 +61.4% YoY

Free Cash Flow -$65.5M +12.1% YoY

Market Cap $226.1M as of Oct 7, 2026

Price / Sales 1.2x on $183.0M revenue, trailing 12 months to June 30, 2026

Price / Earnings 3.8x on $60.0M net income, trailing 12 months to June 30, 2026

Price / Book 5.3x on $42.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MGNX SEC filings page.

MacroGenics, Inc. (MGNX) reported $183.0M in revenue over the twelve months to Jun 30, 2026, up 21.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MGNX FY2025 2026-10-04

The business remains research-led: R&D of $147M supports revenue, while cash use and shrinking equity keep financing central.

The FY2025 operating loss narrowed to $72.8M, but operating cash flow was -$81.0M, showing the accounting improvement did not translate into cash. Reported net income was near break-even in FY2024 and FY2025 despite those operating losses, making net earnings a poor stand-in for operating performance.

R&D was $147M against $149.5M of revenue in FY2025, while SG&A declined; the cost mix remains centered on development rather than commercial overhead. That development-heavy structure helps explain why top-line scale has not yet produced operating profitability.

Debt-to-equity reached 3.6x as equity fell to $55.6M, leaving a thinner equity cushion. Current ratio was 5.1x, while the reported cash-and-investment comparison equaled 8.5 months of annual operating outflow, separating short-term asset coverage from the weaker capital base.

Financial Health Signals

Financial Health Score 57/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of MacroGenics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

MacroGenics, Inc. held $57.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $81.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and MacroGenics, Inc. scores 26/100 among other emerging companies.

Dilution

MacroGenics, Inc. had 64M shares outstanding at the end of fiscal year 2025, against 63M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and MacroGenics, Inc. scores 69/100 among other emerging companies.

R&D Intensity

MacroGenics, Inc. spent $147.2M on research and development in fiscal year 2025, which was 66.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and MacroGenics, Inc. scores 88/100 among other emerging companies.

Revenue Progress

MacroGenics, Inc. reported revenue of $149.5M in fiscal year 2025, against $150.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and MacroGenics, Inc. scores 81/100 among other emerging companies.

Burn Trend

MacroGenics, Inc.'s operations used $81.0M of cash in fiscal year 2025, against $68.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and MacroGenics, Inc. scores 43/100 among other emerging companies.

Balance Sheet

MacroGenics, Inc.'s cash, cash equivalents and investments came to $57.2M at the end of fiscal year 2025, against $201.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and MacroGenics, Inc. scores 32/100 among other emerging companies.

Altman Z-Score Distress

-5.64

MacroGenics, Inc. scores -5.64, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($226.1M) relative to total liabilities ($201.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

MacroGenics, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

MacroGenics, Inc. reported a net loss of $75K while operations used $81.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

MacroGenics, Inc. reported an operating loss of $72.8M against $8.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$32.8M

YoY+378.0%

QoQ+58.0%

5Y CAGR+1.3%

10Y CAGR-8.6%

MacroGenics, Inc. generated $32.8M in revenue in Q2 2026. This represents an increase of 378.0% from the same quarter a year earlier. Against the prior quarter it is up 58.0%.

EBITDA

-$13.1M

YoY+68.2%

QoQ+58.6%

MacroGenics, Inc.'s EBITDA was -$13.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.2% from the same quarter a year earlier. Against the prior quarter it is up 58.6%.

Net Income

$19.5M

YoY+153.8%

QoQ+153.1%

10Y CAGR-7.0%

MacroGenics, Inc. reported $19.5M in net income in Q2 2026. This represents an increase of 153.8% from the same quarter a year earlier. Against the prior quarter it is up 153.1%.

EPS (Diluted)

$0.31

YoY+154.4%

QoQ+153.4%

MacroGenics, Inc. earned $0.31 per diluted share (EPS) in Q2 2026. This represents an increase of 154.4% from the same quarter a year earlier. Against the prior quarter it is up 153.4%.

Cash & Balance Sheet

Free Cash Flow

-$41.6M

YoY+12.9%

QoQ-14.9%

MacroGenics, Inc. recorded an outflow of $41.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 12.9% from the same quarter a year earlier. Against the prior quarter it is down 14.9%.

Cash & Debt

$113.9M

YoY-12.8%

QoQ+71.2%

5Y CAGR-9.6%

10Y CAGR+6.2%

MacroGenics, Inc. held $113.9M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

64M

YoY+0.8%

QoQ+0.2%

5Y CAGR+0.8%

10Y CAGR+6.3%

MacroGenics, Inc. had 64M shares outstanding in Q2 2026. This represents an increase of 0.8% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

-42.2%

MacroGenics, Inc.'s operating margin was -42.2% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

59.4%

10Y change+9.3pp

MacroGenics, Inc.'s net profit margin was 59.4% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

45.5%

YoY+123.3pp

QoQ+219.0pp

5Y change+58.0pp

10Y change+33.3pp

MacroGenics, Inc.'s ROE was 45.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 123.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 219.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$38.8M

YoY-4.9%

QoQ+10.9%

5Y CAGR-7.0%

MacroGenics, Inc. invested $38.8M in research and development in Q2 2026. This represents a decrease of 4.9% from the same quarter a year earlier. Against the prior quarter it is up 10.9%.

Capital Expenditures

$806K

YoY+12.7%

QoQ+134.3%

5Y CAGR-17.2%

10Y CAGR-17.5%

MacroGenics, Inc. invested $806K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 12.7% from the same quarter a year earlier. Against the prior quarter it is up 134.3%.

Share Buybacks

Not reported for Q2 2026.

MGNX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MGNX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$183.0M	$149.5M-0.3%	$150.0M+155.3%	$58.7M-61.3%	$151.9M+96.2%	$77.4M-26.2%	$104.9M+63.4%	$64.2M+6.8%	$60.1M-61.9%	$157.7M+71.7%	$91.9M-8.9%	$100.9M+111.0%	$47.8M-17.6%	$58.0M-9.1%	$63.8M+11.6%	$57.2M
Cost of Revenue	N/A	$0-100.0%	$847K+36.8%	$619K-81.5%	$3.4M+26.4%	$2.7M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$149.5M+0.3%	$149.1M+156.5%	$58.1M-60.9%	$148.6M+98.7%	$74.8M-28.7%	$104.9M+63.4%	$64.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$140.4M	$147.2M-16.9%	$177.2M+6.4%	$166.6M-19.5%	$207.0M-3.5%	$214.6M+11.1%	$193.2M-1.1%	$195.3M+2.3%	$190.8M+29.6%	$147.2M+20.6%	$122.1M+24.2%	$98.3M+40.0%	$70.2M+50.7%	$46.6M+2.5%	$45.4M+10.6%	$41.1M
SG&A Expenses	$36.8M	$39.2M-44.9%	$71.0M+36.1%	$52.2M-11.5%	$58.9M-6.5%	$63.0M+47.4%	$42.7M-7.2%	$46.1M+13.7%	$40.5M+24.0%	$32.7M+9.5%	$29.8M+31.0%	$22.8M+42.9%	$15.9M+43.6%	$11.1M+8.8%	$10.2M-6.3%	$10.9M
Operating Income	-$34.3M	-$72.8M+34.1%	-$110.6M+34.3%	-$168.2M-38.6%	-$121.4M+40.1%	-$202.8M-54.7%	-$131.1M+26.0%	-$177.2M-3.5%	-$171.2M-673.2%	-$22.1M+63.1%	-$60.0M-197.5%	-$20.2M+47.3%	-$38.3M-10568.6%	$366K-95.5%	$8.2M+56.3%	$5.2M
EBITDA	N/A	-$65.7M+36.3%	-$103.0M+35.0%	-$158.6M-44.8%	-$109.6M+42.8%	-$191.5M-60.8%	-$119.1M+27.8%	-$164.9M-1.7%	-$162.0M-986.5%	-$14.9M+71.6%	-$52.4M-202.8%	-$17.3M+52.5%	-$36.5M-2430.3%	$1.6M-83.0%	$9.2M+45.0%	$6.3M
Interest Expense	$16.9M	$8.5M+663.0%	$1.1M-22.0%	$1.4M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	-$672K-171.2%	$944K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	$60.0M	-$75K-11.4%	-$67K-639.3%	-$9K+100.0%	-$119.8M+40.7%	-$202.1M-55.8%	-$129.7M+14.5%	-$151.8M+11.5%	-$171.5M-773.6%	-$19.6M+66.5%	-$58.5M-190.6%	-$20.1M+47.4%	-$38.3M-14579.3%	-$261K-103.1%	$8.4M+24.5%	$6.7M
EPS (Basic)	N/A	-$1.18-10.3%	-$1.07-613.3%	-$0.15+92.3%	-$1.95+42.1%	-$3.37-36.4%	-$2.47+21.8%	-$3.16	N/A	N/A	N/A	N/A	-$1.40-3400.0%	-$0.04	$0.00	$0.00
EPS (Diluted)	-$0.22	-$1.18-10.3%	-$1.07-613.3%	-$0.15	-$1.95+42.1%	-$3.37-36.4%	-$2.47+21.8%	-$3.16	N/A	N/A	N/A	N/A	-$1.40	-$0.04	$0.00	$0.00
Diluted Shares (Avg)	N/A	63M+0.9%	63M+1.1%	62M	61M+2.5%	60M+14.3%	52M+9.1%	48M	N/A	36M+4.1%	35M+9.1%	32M+16.1%	27M	7M	1M+5.6%	1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$32.8M+378.0%	$20.8M+57.5%	$56.6M+192.5%	$72.8M-34.2%	$6.9M-36.4%	$13.2M+44.9%	$19.4M+80.5%	$110.7M+964.8%
Cost of Revenue	N/A	N/A	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$233K+42.9%	$168K+97.6%
Gross Profit	N/A	N/A	$56.6M+196.0%	$72.8M-34.1%	$6.9M-35.3%	$13.2M+49.3%	$19.1M+81.1%	$110.5M+972.0%
R&D Expenses	$38.8M-4.9%	$35.0M-11.9%	$34.0M-12.6%	$32.7M-19.3%	$40.8M-21.1%	$39.7M-13.8%	$38.9M-17.9%	$40.5M+34.6%
SG&A Expenses	$7.9M-15.0%	$9.7M-9.4%	$9.2M-66.8%	$9.9M-29.8%	$9.3M-35.5%	$10.7M-27.1%	$27.8M+121.4%	$14.1M+13.7%
Operating Income	-$13.9M+68.0%	-$33.4M+21.5%	-$5.6M+89.3%	$18.6M-65.6%	-$43.2M+25.7%	-$42.6M+20.7%	-$52.8M-7.1%	$54.2M+252.6%
EBITDA	-$13.1M+68.2%	-$31.8M+22.3%	-$3.9M+92.3%	$20.4M-63.5%	-$41.3M+26.7%	-$40.9M+21.3%	-$50.8M-7.0%	$56.0M+267.0%
Interest Expense	$4.4M+448.1%	$4.9M+5272.5%	$4.3M+17904.2%	$3.3M	$802K+13266.7%	$91K-92.0%	-$24K	$0
Income Tax	$0-100.0%	N/A	N/A	$0	$105K	N/A	N/A	$0
Net Income	$19.5M+153.8%	-$36.8M+10.4%	$60.4M+17.3%	$16.8M-70.1%	-$36.3M+34.9%	-$41.0M+21.4%	$51.5M+239.0%	$56.3M+220.8%
EPS (Basic)	$0.31+154.4%	-$0.58+10.8%	-$0.22+12.0%	$0.27-70.0%	-$0.57+36.0%	-$0.65+22.6%	-$0.25+66.7%	$0.90+221.4%
EPS (Diluted)	$0.31+154.4%	-$0.58+10.8%	-$0.22+12.0%	$0.27-70.0%	-$0.57+36.0%	-$0.65+22.6%	-$0.25+66.7%	$0.90+221.4%
Diluted Shares (Avg)	64M+0.7%	63M+0.8%	N/A	63M+0.7%	63M+0.8%	63M+1.1%	N/A	63M+1.0%

MGNX Balance Sheet

MGNX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$256.8M-1.8%	$261.7M-12.3%	$298.4M+6.4%	$280.5M-16.3%	$335.2M-11.5%	$378.7M+21.2%	$312.5M-5.9%	$332.1M-11.2%	$373.9M+20.1%	$311.3M-13.4%	$359.3M+106.6%	$173.9M+38.2%	$125.8M+134.0%	$53.7M	N/A
Current Assets	$219.9M+1.1%	$217.5M-13.5%	$251.3M+13.1%	$222.2M-20.5%	$279.6M-10.6%	$312.6M+30.4%	$239.8M-10.9%	$269.1M-16.5%	$322.3M+13.5%	$283.9M-17.1%	$342.4M+107.8%	$164.7M+37.9%	$119.5M+139.3%	$49.9M	N/A
Cash & Equivalents	$57.2M-68.7%	$182.8M+81.1%	$101.0M-7.3%	$108.9M-11.8%	$123.5M-31.8%	$181.1M+43.2%	$126.5M-42.5%	$220.1M+4.0%	$211.7M+151.8%	$84.1M-57.1%	$196.2M+24.5%	$157.6M+35.3%	$116.5M+144.0%	$47.7M-13.5%	$55.2M
Short-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$89.3M+601.1%	$12.7M-86.4%	$93.4M-51.6%	$192.9M+35.0%	$142.9M	$0	$0	$0	$0
Inventory	$7.9M	$0-100.0%	$1.2M-15.9%	$1.5M-66.9%	$4.4M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$427K-90.1%	$4.3M-58.4%	$10.4M-81.6%	$56.2M+441.3%	$10.4M-55.0%	$23.1M+81.1%	$12.7M-56.9%	$29.6M+116.8%	$13.6M+393.6%	$2.8M+125.8%	$1.2M-58.3%	$2.9M+46.5%	$2.0M-2.1%	$2.0M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$8.0M	$0	$0	$0	$0	$0
Total Liabilities	$201.3M+38.2%	$145.6M-0.1%	$145.8M+5.3%	$138.5M+44.8%	$95.6M+15.4%	$82.9M+1.2%	$81.9M-8.3%	$89.3M+19.6%	$74.6M+75.6%	$42.5M-7.4%	$45.9M-12.7%	$52.6M+12.2%	$46.9M-24.4%	$62.0M	N/A
Current Liabilities	$43.1M-22.4%	$55.5M-1.0%	$56.1M+15.4%	$48.6M-34.8%	$74.6M+47.2%	$50.7M+12.2%	$45.2M-24.6%	$59.9M+20.5%	$49.8M+82.2%	$27.3M+12.8%	$24.2M-10.7%	$27.1M-6.0%	$28.8M-3.0%	$29.7M	N/A
Non-Current Liabilities	$158.1M+75.6%	$90.1M+0.4%	$89.7M-0.2%	$89.8M+326.8%	$21.0M-34.6%	$32.2M-12.3%	$36.7M+25.2%	$29.3M+17.8%	$24.9M+63.6%	$15.2M-30.0%	$21.7M-14.8%	$25.5M+41.3%	$18.0M-44.1%	$32.3M	N/A
Total Equity	$55.6M-52.1%	$116.1M-24.0%	$152.6M+7.5%	$142.0M-40.7%	$239.6M-19.0%	$295.9M+28.3%	$230.6M-5.0%	$242.9M-18.8%	$299.2M+11.3%	$268.8M-14.2%	$313.3M+158.3%	$121.3M+53.7%	$78.9M+1057.9%	-$8.2M+52.9%	-$17.5M
Retained Earnings	-$1.2B-6.4%	-$1.2B-6.1%	-$1.1B-0.8%	-$1.1B-12.3%	-$973.9M-26.2%	-$771.8M-20.2%	-$642.1M-31.0%	-$490.3M-57.0%	-$312.3M-6.7%	-$292.7M-25.0%	-$234.2M-9.4%	-$214.0M-21.8%	-$175.7M-0.1%	-$175.5M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$345.4M+40.7%	$217.9M-3.0%	$256.8M-1.8%	$270.8M+2.4%	$245.4M+22.0%	$224.6M-9.6%	$261.7M-12.3%	$264.5M-22.2%
Current Assets	$321.7M+57.0%	$182.5M+0.2%	$219.9M+1.1%	$232.1M+4.5%	$204.9M+30.6%	$182.1M-10.1%	$217.5M-13.5%	$222.2M-23.7%
Cash & Equivalents	$113.9M-12.8%	$66.5M-54.3%	$57.2M-68.7%	$80.1M-55.4%	$130.7M+55.7%	$145.6M+81.2%	$182.8M+81.1%	$179.6M+99.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	$9.5M+0.8%	$7.9M	$8.8M+169.7%	$9.3M+731.8%	$9.4M+655.3%	$0-100.0%	$3.2M+204.3%
Accounts Receivable	$24.6M+96.3%	$10.4M-1.1%	$427K-90.1%	$69.2M+691.2%	$12.5M+102.4%	$10.5M+46.0%	$4.3M-58.4%	$8.8M-65.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$302.5M+52.2%	$196.7M+35.2%	$201.3M+38.2%	$203.8M+41.1%	$198.8M+38.7%	$145.4M+2.3%	$145.6M-0.1%	$144.4M-1.1%
Current Liabilities	$108.8M+179.0%	$95.9M+73.0%	$43.1M-22.4%	$44.5M-25.0%	$39.0M-32.6%	$55.4M-0.6%	$55.5M-1.0%	$59.3M+15.6%
Non-Current Liabilities	$193.7M+21.2%	$100.7M+11.9%	$158.1M+75.6%	$159.3M+87.1%	$159.8M+87.1%	$90.0M+4.2%	$90.1M+0.4%	$85.1M-10.1%
Total Equity	$42.9M-8.0%	$21.2M-73.2%	$55.6M-52.1%	$67.0M-44.2%	$46.6M-19.4%	$79.1M-25.5%	$116.1M-24.0%	$120.1M-38.1%
Retained Earnings	-$1.3B-1.2%	-$1.3B-5.8%	-$1.2B-6.4%	-$1.2B-6.6%	-$1.2B-3.0%	-$1.2B-4.8%	-$1.2B-6.1%	-$1.2B-9.2%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

MGNX Cash Flow Statement

MGNX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$63.7M	-$81.0M-18.5%	-$68.4M+12.6%	-$78.2M+10.1%	-$87.0M+39.5%	-$143.8M-28.5%	-$111.9M+16.7%	-$134.3M+12.4%	-$153.2M-1163.8%	$14.4M+133.0%	-$43.7M-219.7%	-$13.7M+58.3%	-$32.8M-131.2%	-$14.2M-115.3%	-$6.6M-197.4%	$6.8M
Depreciation & Amortization	N/A	$7.2M-4.9%	$7.5M-21.8%	$9.6M-18.7%	$11.9M+5.4%	$11.3M-5.8%	$12.0M-2.8%	$12.3M+34.3%	$9.2M+26.7%	$7.2M-5.0%	$7.6M+165.7%	$2.9M+57.1%	$1.8M+51.8%	$1.2M+20.0%	$1.0M-9.1%	$1.1M
Stock-Based Compensation	N/A	$14.3M-51.5%	$29.4M+60.2%	$18.4M-10.1%	$20.4M-11.6%	$23.1M+11.8%	$20.7M+5.6%	$19.6M+18.5%	$16.5M+12.0%	$14.7M+21.2%	$12.2M+55.0%	$7.8M+141.9%	$3.2M+276.3%	$862K+2.9%	$838K-64.3%	$2.3M
Capital Expenditures	$1.8M	$1.9M-48.4%	$3.7M+110.1%	$1.8M-51.3%	$3.6M-41.6%	$6.2M+5.0%	$5.9M+37.7%	$4.3M-82.8%	$25.0M-15.1%	$29.4M+158.4%	$11.4M+23.7%	$9.2M+157.5%	$3.6M+20.6%	$3.0M+215.0%	$940K+87.9%	$500K
Free Cash Flow	-$65.5M	-$83.0M-15.1%	-$72.1M+9.9%	-$80.0M+11.7%	-$90.6M+39.6%	-$150.0M-27.4%	-$117.8M+15.0%	-$138.6M+22.2%	-$178.2M-1088.1%	-$15.0M+72.8%	-$55.1M-140.9%	-$22.9M+37.1%	-$36.3M-112.1%	-$17.1M-127.8%	-$7.5M-220.2%	$6.3M
Investing Cash Flow	-$13.1M	-$114.1M-176.4%	$149.3M+286.4%	-$80.1M-213.2%	$70.7M+293.2%	-$36.6M-370.3%	-$7.8M+90.2%	-$79.4M-240.1%	$56.6M-27.3%	$77.9M	N/A	N/A	N/A	-$3.0M-215.0%	-$940K-87.9%	-$500K
Financing Cash Flow	$60.0M	$69.5M+7141.0%	$960K-99.4%	$150.4M+8963.4%	$1.7M-98.6%	$122.8M-29.6%	$174.3M+45.3%	$120.0M+14.3%	$105.0M+197.0%	$35.3M	N/A	N/A	N/A	$85.9M+183283.5%	$47K-99.6%	$12.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$40.7M+13.3%	-$35.8M+23.6%	$43.0M+212.0%	-$30.2M-150.2%	-$47.0M-5.6%	-$46.9M-2.7%	-$38.4M-37.0%	$60.2M+270.7%
Depreciation & Amortization	$708K-62.9%	$1.7M-4.7%	$1.7M-17.0%	$1.8M-2.5%	$1.9M+5.3%	$1.8M-3.8%	$2.1M+8.1%	$1.8M-5.9%
Stock-Based Compensation	$2.0M-46.5%	$2.6M-39.7%	N/A	$3.5M-40.6%	$3.7M-44.5%	$4.4M-21.0%	N/A	$6.0M+24.6%
Capital Expenditures	$806K+12.7%	$344K-35.0%	$244K-60.6%	$426K-28.0%	$715K-30.9%	$529K-63.7%	$620K0.0%	$592K+18.6%
Free Cash Flow	-$41.6M+12.9%	-$36.2M+23.8%	$42.8M+209.6%	-$30.6M-151.4%	-$47.7M-4.8%	-$47.4M-0.7%	-$39.0M-36.2%	$59.6M+266.7%
Investing Cash Flow	$28.0M+174.3%	$45.3M+357.7%	-$66.0M-259.1%	-$20.4M-157.2%	-$37.6M-179.3%	$9.9M-60.1%	$41.5M+6.8%	$35.6M+206.2%
Financing Cash Flow	$60.2M-13.7%	-$207K+26.6%	$57K-63.2%	$0+100.0%	$69.7M+11058.2%	-$282K-213.7%	$155K-43.2%	-$68K-100.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MGNX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MGNX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	100.0%+0.6pp	99.4%+0.5pp	99.0%+1.2pp	97.8%+1.2pp	96.6%-3.4pp	100.0%0.0pp	100.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-48.7%+25.0pp	-73.7%	-286.4%	-79.9%	-261.9%	-125.0%	-276.0%	-284.8%	-14.0%+51.3pp	-65.3%-45.3pp	-20.0%+60.1pp	-80.2%-80.8pp	0.6%-12.2pp	12.9%+3.7pp	9.2%
Net Margin	-0.1%0.0pp	0.0%0.0pp	0.0%+78.8pp	-78.8%	-261.0%	-123.7%	-236.5%	-285.2%	-12.4%+51.3pp	-63.7%-43.7pp	-20.0%+60.2pp	-80.2%-79.7pp	-0.4%-13.6pp	13.1%+1.4pp	11.7%
Return on Equity	-0.1%-0.1pp	-0.1%0.0pp	0.0%+84.3pp	-84.3%0.0pp	-84.4%-40.5pp	-43.9%+22.0pp	-65.8%+4.8pp	-70.6%-64.0pp	-6.6%+15.2pp	-21.8%-15.3pp	-6.4%+25.2pp	-31.6%-31.3pp	-0.3%	N/A	N/A
Return on Assets	0.0%0.0pp	0.0%0.0pp	0.0%+42.7pp	-42.7%+17.6pp	-60.3%-26.0pp	-34.3%+14.3pp	-48.6%+3.0pp	-51.6%-46.4pp	-5.3%+13.6pp	-18.8%-13.2pp	-5.6%+16.4pp	-22.0%-21.8pp	-0.2%-15.8pp	15.6%	N/A
Current Ratio	5.10+1.2x	3.92-0.6x	4.48-0.1x	4.57+0.8x	3.75-2.4x	6.17+0.9x	5.31+0.8x	4.49-2.0x	6.48-3.9x	10.40-3.7x	14.15+8.1x	6.08+1.9x	4.14+2.5x	1.68	N/A
Debt-to-Equity	3.62+2.4x	1.25+0.3x	0.960.0x	0.97+0.6x	0.40+0.1x	0.28-0.1x	0.350.0x	0.37+0.1x	0.25+0.1x	0.160.0x	0.15-0.3x	0.43-0.2x	0.59	N/A	N/A
Asset Turnover	0.580.0x	0.57+0.4x	0.20-0.3x	0.54+0.3x	0.230.0x	0.28+0.1x	0.210.0x	0.18-0.2x	0.42+0.1x	0.300.0x	0.280.0x	0.27-0.2x	0.46-0.7x	1.19	N/A
FCF Margin	-55.5%-7.4pp	-48.1%	-136.1%	-59.6%	-193.7%	-112.3%	-215.9%	-296.4%	-9.5%+50.4pp	-59.9%-37.3pp	-22.7%+53.3pp	-76.0%-46.5pp	-29.5%-17.7pp	-11.8%-22.7pp	10.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	N/A	N/A	100.0%+1.2pp	100.0%+0.1pp	100.0%+1.6pp	100.0%+3.0pp	98.8%+0.3pp	99.9%+0.7pp
Operating Margin	-42.2%	-161.0%	-10.0%	25.6%-23.4pp	-629.3%	-323.1%	-273.0%	48.9%
Net Margin	59.4%	-177.0%	106.7%	23.1%-27.8pp	-527.8%	-311.1%	266.0%	50.9%
Return on Equity	45.5%+123.3pp	-173.5%-121.6pp	108.6%+64.3pp	25.1%-21.8pp	-77.8%+18.5pp	-51.9%-2.7pp	44.4%+68.6pp	46.9%+37.8pp
Return on Assets	5.7%+20.4pp	-16.9%+1.4pp	23.5%+3.8pp	6.2%-15.1pp	-14.8%+12.9pp	-18.3%+2.7pp	19.7%+32.1pp	21.3%+16.1pp
Current Ratio	2.96-2.3x	1.90-1.4x	5.10+1.2x	5.22+1.5x	5.25+2.5x	3.28-0.3x	3.92-0.6x	3.75-1.9x
Debt-to-Equity	7.06+2.8x	9.28+7.4x	3.62+2.4x	3.04+1.8x	4.26+1.8x	1.84+0.5x	1.25+0.3x	1.20+0.5x
Asset Turnover	0.10+0.1x	0.100.0x	0.22+0.1x	0.27-0.1x	0.030.0x	0.060.0x	0.070.0x	0.42+0.4x
FCF Margin	-126.6%	-174.0%	75.6%	-42.0%-95.8pp	-694.4%	-359.4%	-201.7%	53.8%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
MacroGenics, Inc. MGNX	FY2025	$149.5M	-$75K	-0.1%	$226.1M	57/100
Spero Therapeutics, Inc. SPRO	FY2025	$66.8M	$8.6M	12.8%	$69.3M	65/100
Atossa Therapeutics, Inc. ATOS	FY2025	N/A	-$34.8M	N/A	$24.4M	—
TScan Therapeutics, Inc. TCRX	FY2025	$10.3M	-$129.8M	N/A	$18.7M	38/100
HilleVax, Inc. HLVX	FY2024	N/A	-$147.3M	N/A	$104.8M	—
InflaRx N.V. IFRX	FY2025	$20K	N/A	N/A	$232.8M	—

Where MacroGenics, Inc. Ranks

Frequently Asked Questions

What is MacroGenics, Inc.'s annual revenue?

MacroGenics, Inc. (MGNX) reported $149.5M in total revenue for fiscal year 2025. This represents a -0.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MacroGenics, Inc.'s revenue growing?

MacroGenics, Inc. (MGNX) revenue declined by 0.3% year-over-year, from $150.0M to $149.5M in fiscal year 2025.

Is MacroGenics, Inc. profitable?

No, MacroGenics, Inc. (MGNX) reported a net income of -$75K in fiscal year 2025, with a net profit margin of -0.1%.

What is MacroGenics, Inc.'s EBITDA?

MacroGenics, Inc. (MGNX) had EBITDA of -$65.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is MacroGenics, Inc.'s gross margin?

MacroGenics, Inc. (MGNX) had a gross margin of 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is MacroGenics, Inc.'s operating margin?

MacroGenics, Inc. (MGNX) had an operating margin of -48.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is MacroGenics, Inc.'s net profit margin?

MacroGenics, Inc. (MGNX) had a net profit margin of -0.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is MacroGenics, Inc.'s return on equity (ROE)?

MacroGenics, Inc. (MGNX) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is MacroGenics, Inc.'s free cash flow?

MacroGenics, Inc. (MGNX) recorded an outflow of $83.0M in free cash flow during fiscal year 2025. This represents a -15.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is MacroGenics, Inc.'s operating cash flow?

MacroGenics, Inc. (MGNX) recorded an outflow of $81.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are MacroGenics, Inc.'s total assets?

MacroGenics, Inc. (MGNX) had $256.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are MacroGenics, Inc.'s capital expenditures?

MacroGenics, Inc. (MGNX) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does MacroGenics, Inc. spend on research and development?

MacroGenics, Inc. (MGNX) invested $147.2M in research and development during fiscal year 2025.

How many shares does MacroGenics, Inc. have outstanding?

MacroGenics, Inc. (MGNX) had 64M shares outstanding as of fiscal year 2025.

What is MacroGenics, Inc.'s current ratio?

MacroGenics, Inc. (MGNX) had a current ratio of 5.10 as of fiscal year 2025, which is generally considered healthy.

What is MacroGenics, Inc.'s debt-to-equity ratio?

MacroGenics, Inc. (MGNX) had a debt-to-equity ratio of 3.62 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is MacroGenics, Inc.'s return on assets (ROA)?

MacroGenics, Inc. (MGNX) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is MacroGenics, Inc.'s P/E ratio?

MacroGenics, Inc. (MGNX) trades at 3.8x earnings, its market capitalization divided by net income of $60.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $226.1M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MacroGenics, Inc.'s price-to-sales ratio?

MacroGenics, Inc. (MGNX) trades at 1.2x sales, its market capitalization divided by revenue of $183.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $226.1M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does MacroGenics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, MacroGenics, Inc. (MGNX) held $57.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $81.0M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is MacroGenics, Inc.'s Altman Z-Score?

MacroGenics, Inc. (MGNX) has an Altman Z-Score of -5.64, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is MacroGenics, Inc.'s Piotroski F-Score?

MacroGenics, Inc. (MGNX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are MacroGenics, Inc.'s earnings high quality?

MacroGenics, Inc. (MGNX) reported a net loss of $75K while operations used $81.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can MacroGenics, Inc. cover its interest payments?

MacroGenics, Inc. (MGNX) reported an operating loss of $72.8M against $8.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is MacroGenics, Inc.?

MacroGenics, Inc. (MGNX) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.